Quantum Genomics SA: Clinical Trials

4 trials sponsored by Quantum Genomics SA, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1

Follow Quantum Genomics SA: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Ramipril, Firibastat - Myocardial Infarction
Phase 2CompletedQuantum Genomics SA2952019-06-042023-02-27
Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
QGC001 - Hypertension
Phase 2CompletedQuantum Genomics SA2562017-10-132018-12-11
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
QGC001, Placebo - Heart Failure
Phase 2TerminatedQuantum Genomics SA232016-06-012018-10-16
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
QGC001, Placebo - Essential Hypertension
Phase 2CompletedQuantum Genomics SA342015-01-012016-09-28

Conditions studied

Essential Hypertension (1)  ·  Heart Failure (1)  ·  Hypertension (1)  ·  Myocardial Infarction (1)

Interventions

Ramipril (1)  ·  firibastat (1)

Countries

France (3)  ·  Germany (2)  ·  Hungary (2)  ·  Poland (2)  ·  United Kingdom (2)  ·  Czechia (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Slovakia (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Faiez Zannad, MD (1)  ·  Gilles Montalescot, MD, PhD (1)  ·  Keith C. Ferdinand, MD FACC (1)

Results publications

PMID 33027067, PMID 30882604, PMID 31014072, PMID 31923435, PMID 36757536